Viewing Study NCT06513234

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:33 AM
Ignite Modification Date: 2026-03-01 @ 12:07 PM
Study NCT ID: NCT06513234
Status: RECRUITING
Last Update Posted: 2024-07-22
First Post: 2024-07-01
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Marginal Zone Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None orelabrutinib View
None Marginal Zone Lymphomas View
None obinutuzumab View